Clinical Trials Logo
  1. Home
  2. Carcinoma, Small Cell
  3. NCT00129974

Study of Pemetrexed and Gemcitabine for Patients With a New Diagnosis of Extensive-Stage Small Cell Lung Cancer

Carcinoma, Small Cell Clinical Trial

Official title:
A Phase II Trial of Pemetrexed in Combination With Gemcitabine as First Line Treatment in Extensive-Stage Small Cell Lung Carcinoma

Clinical Trial Summary

The purpose of the study is to determine whether pemetrexed and gemcitabine cause good tumour shrinkage when given to patients with previously untreated extensive-stage small cell lung cancer. The second purpose is to see if the side effects appear better than what is expected with standard chemotherapy.

Clinical Trial Description

Extensive-stage small cell lung carcinoma is incurable. Present therapies are toxic and responses are short lived. This phase II, single arm, window of opportunity study will assess the response rate and toxicity of pemetrexed and gemcitabine in this cohort. ;

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00129974
Study type Interventional
Source Tufts Medical Center
Contact
Status Terminated
Phase Phase 2
Start date August 2005
View Details
See also
  Status Clinical Trial Phase
Completed NCT01860898 - A Phase I Study of iPS Cell Generation From Patients With COPD N/A
Completed NCT00046787 - Efficacy and Safety Study of OSI-211 (Liposomal Lurtotecan) to Treat Recurrent Small Cell Lung Cancer Phase 2
Recruiting NCT03212404 - Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers Phase 1
Recruiting NCT03554473 - M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers Phase 1/Phase 2
Terminated NCT00094978 - Depsipeptide/Flavopiridol Infusion for Cancers of the Lungs, Esophagus, Pleura, Thymus or Mediastinum Phase 1
Recruiting NCT04162041 - Topotecan Plus M6620 (VX-970) vs. Topotecan Alone in People With Relapsed Small-Cell Lung Cancer Phase 2
Completed NCT03092739 - A Study to Assess Programmed Death Ligand-1 (PD-L1) Expression in Cytological Versus Histological Lung Cancer Specimens
Completed NCT00305942 - Topotecan and Carboplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer Phase 2
Terminated NCT00324558 - Adjuvant BEmiparin in Small Cell Lung Carcinoma (ABEL STUDY) Phase 2
Completed NCT00359359 - A Study of a New Chemotherapy Agent in Combination With Cisplatin to Treat Small Cell Lung Cancer Phase 1/Phase 2
Completed NCT00191750 - A Study of Pemetrexed in Small Cell Lung Cancer, Which Has Returned Phase 2
Recruiting NCT05461430 - Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
Recruiting NCT02366741 - Neurocognitive Function After Prophylactic Cranial Irradiation & Hippocampal Sparing in LD SCLC Patients - a Pilot Study N/A
Active, not recruiting NCT01900951 - Temozolomide as Maintenance Therapy in Small Cell Lung Cancer Phase 2
Completed NCT00826644 - Trial of Belotecan/Cisplatin in Chemotherapy Naive Small Cell Lung Cancer Patient Phase 3
Completed NCT00284154 - Vinflunine in the Treatment of Patients With Relapsed Extensive Small Cell Lung Cancer Phase 2
Recruiting NCT00100256 - Rhenium Re 188 P2045 in Patients With Lung Cancer Who Have Received or Refused to Receive Prior Chemotherapy Phase 1/Phase 2
Completed NCT00126828 - Study of Radiation Dose Intensity Concurrent With Chemotherapy For Limited Stage Small Cell Lung Cancer Phase 1/Phase 2
Terminated NCT02034123 - Investigation of GSK2879552 in Subjects With Relapsed/Refractory Small Cell Lung Carcinoma Phase 1
Recruiting NCT05500391 - Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring Phase 2